- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Frontline Cabozantinib Bests Sunitinib in mRCC
October 11th 2016, 12:35am
Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.
Adjuvant Sunitinib Extends DFS in High-Risk RCC
October 10th 2016, 10:15am
Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.
Atezolizumab Significantly Extends Survival in NSCLC
October 10th 2016, 12:14am
Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.
Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC
October 9th 2016, 11:41pm
Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.
Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval
October 9th 2016, 11:24pm
Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.
Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer
October 9th 2016, 10:55pm
ESMO Congress: Gynecologic Cancers
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.
Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC
October 9th 2016, 10:51pm
Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.
Frontline Pembrolizumab Data Is Practice Changing for NSCLC
October 9th 2016, 10:15am
Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.
Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer
October 9th 2016, 12:08am
ESMO Congress: Gynecologic Cancers
A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.
Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma
October 8th 2016, 11:30pm
Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.
Dr. Bruix on the Phase III RESORCE Trial in HCC
October 8th 2016, 11:26pm
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.
Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib
October 8th 2016, 10:14pm
The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer
October 8th 2016, 8:47pm
Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.
Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer
October 8th 2016, 10:20am
ESMO Congress: Gynecologic Cancers
Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.
Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma
October 8th 2016, 10:15am
Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.
Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer
October 8th 2016, 12:09am
Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.
Dr. Bastholt on Lenvatinib in NSCLC
October 8th 2016, 12:01am
Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.
High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer
October 7th 2016, 11:52pm
ESMO Congress: Gynecologic Cancers
The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.
Neoadjuvant Anti-PD-1 Therapy Active in NSCLC
October 7th 2016, 10:53pm
Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.
Thousands of Melanoma Patients in Europe Not Receiving Novel Agents
October 7th 2016, 10:37pm
Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.